Magenta Therapeutics

The company's business model was centered on the research and development of a pipeline of novel medicines. This involved significant investment in clinical trials to validate the safety and efficacy of its product candidates. Magenta's portfolio included programs aimed at three critical areas of transplantation: patient conditioning, stem cell mobilization, and cell therapy manufacturing. One of its lead programs was MGTA-117, an antibody-drug conjugate designed to precisely deplete stem and immune cells before a transplant, aiming to reduce the reliance on harsh chemotherapy and radiation. Another key candidate was MGTA-145, developed to enable the rapid and reliable mobilization of stem cells from the bone marrow to the bloodstream for collection. The company pursued collaborations with other pharmaceutical and biotechnology firms, such as bluebird bio and Takeda, to advance its programs and technology platforms.

After raising significant funding, including a $50 million Series B in 2017 and a total of $150 million over four rounds, Magenta went public. However, the company faced a critical setback in January 2023 when it voluntarily paused a Phase 1/2 clinical trial for its lead candidate, MGTA-117, following the death of a trial participant. This event led to a comprehensive review of the business, resulting in the decision to halt all program development, lay off approximately 84% of its workforce, and explore strategic alternatives. In September 2023, Magenta Therapeutics completed a reverse merger with Dianthus Therapeutics. The combined entity now operates under the Dianthus Therapeutics name, focusing on Dianthus's portfolio of immunology drugs, and trades on Nasdaq under the ticker "DNTH".